Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Abbott Laboratories : Patent Issued for Shelf-Stable, Clear Liquid Nutritional Compositions Comprising Epigallocatechin Gallate (EGCG) and Methods for Preparing the Same...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/22/2017 | 09:01pm CEST

Patent Issued for Shelf-Stable, Clear Liquid Nutritional Compositions Comprising Epigallocatechin Gallate (EGCG) and Methods for Preparing the Same (USPTO 9675097)

By a News Reporter-Staff News Editor at Drug Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Patel, Gaurav (Gahanna, OH); Johns, Paul (Columbus, OH); Dewille, Normanella (Columbus, OH); Pereira, Suzette (Westerville, OH), filed on October 4, 2013, was published online on June 13, 2017 (see also ABBOTT LABORATORIES).

The assignee for this patent, patent number 9675097, is ABBOTT LABORATORIES (Abbott Park, IL).

Reporters obtained the following quote from the background information supplied by the inventors: "Consumers can improve their overall health and well-being by consuming nutritional products containing a balance of protein, carbohydrates, vitamins, minerals, and other nutrients. Shelf-stable liquid nutritional compositions are a popular form of such nutritional products. Shelf-stable products are generally prepared and packaged in a manner that extends the shelf-life of the product and that also allows the packaged product to be safely stored at room or ambient temperature for long durations (e.g., more than twelve months).

"The nutritional products are often formulated with certain active ingredients that help tailor the product to a specific therapeutic or nutritional benefit. Epigallocatechin gallate, also known as EGCg (or epigallocatechin 3-gallate), has been identified as one such beneficial active ingredient. However, the EGCg present in certain protein-containing liquid nutritional compositions can be sensitive to preparation techniques involving high temperatures, such as aseptic or retort sterilization techniques, generally used to obtain the shelf-stable product. EGCg present in these certain compositions will epimerize, chemically degrade (e.g., hydrolyze or oxidize), or both epimerize and chemically degrade when subjected to the high temperatures generally associated with aseptic or retort sterilization."

In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "Disclosed herein are shelf-stable, clear liquid nutritional compositions and methods for preparing the shelf-stable, clear liquid nutritional compositions. Embodiments of the shelf-stable, clear liquid nutritional compositions are sterilized or stabilized and have a pH ranging from 2.5 to 4.6. The shelf-stable, clear liquid nutritional compositions include water, a source of EGCg, and a source of protein. The shelf-stability of the composition is exhibited by the lack of epimerization and degradation products of the EGCg present in the sterilized composition. In particular, the shelf-stable, clear liquid nutritional products disclosed herein lose no more than 20% by weight solids of the EGCg content present in the initial formulation of the composition to epimerization, degradation, or both epimerization and degradation during heat sterilization. In certain embodiments, the loss of EGCg is exhibited by the amount of epimerization product gallocatechin gallate ('GCg') present in the composition following heat sterilization.

"In accordance with certain embodiments of the shelf-stable, clear liquid nutritional compositions disclosed herein, a sterilized, clear liquid nutritional composition is provided. The composition comprises water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg (in the sterilized, clear liquid nutritional composition); and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein (in the sterilized, clear liquid nutritional composition). The pH of the composition ranges from 2.5 to 4.6. The composition contains no more than 340 mg/L of GCg and is clear after sterilization.

"In another embodiment, a method for preparing a sterilized, clear liquid nutritional composition is provided. The method comprises heating an unsterilized liquid nutritional composition having a pH ranging from 2.5 to 4.6 to a temperature ranging from 85.degree. C. (185.degree. F.) to 152.degree. C. (306.degree. F.) for a period of time sufficient to produce a sterilized liquid nutritional composition. The sterilized liquid nutritional composition comprises water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg (in the sterilized, clear liquid nutritional composition); and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein (in the sterilized, clear liquid nutritional composition). The sterilized liquid nutritional composition contains no more than 340 mg/L of GCg.

"In another embodiment, a method for preparing a sterilized, clear liquid nutritional composition is provided. The method comprises admixing at least one source of epigallocatechin gallate (EGCg) and at least one source of whey-based protein containing .beta.-lactoglobulin to form an admixture, where the admixture comprises EGCg and .beta.-lactoglobulin in amounts sufficient to provide a molar ratio of EGCg to .beta.-lactoglobulin of 1:1 to 11:1 in the admixture. The admixing occurs at a pH of 2.5 to 4.6. The method also includes a step directed to forming an unsterilized liquid nutritional composition by combining the admixture with at least one of the following ingredients: water; an additional source of EGCg; and an additional source of protein selected from the group consisting of whey-based proteins, acidified soy protein isolates, soy protein hydrolysates, casein hydrolysates, pea hydrolysates, and combinations thereof. In addition, the method includes the steps of adjusting the pH of the unsterilized nutritional composition to obtain a pH ranging from 2.5 to 4.6, if necessary, and heating the unsterilized liquid nutritional composition to a temperature ranging from 85.degree. C. (185.degree. F.) to 152.degree. C. (306.degree. F.) for a period of time sufficient to produce a sterilized liquid nutritional composition. The sterilized nutritional composition produced according to this method comprises water, 200-1700 mg/L of total EGCg, 25-45 g/L of total protein, and no more than 340 mg/L of gallocatechin gallate (GCg).

"In another embodiment, a stabilized, clear liquid nutritional composition is provided. The composition comprises water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of an initial amount of EGCg; and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein. The at least one source of protein comprises .beta.-lactoglobulin in an amount sufficient to provide a molar ratio of EGCg to .beta.-lactoglobulin of 1:1 to 11:1 in the composition. The pH of the composition ranges from 2.5 to 4.6. The liquid nutritional composition is sufficiently stable such that it will lose no more than 20% by weight solids of the initial amount of EGCg in the liquid nutritional composition if heated to a temperature ranging from 85.degree. C. (185.degree. F.) to 152.degree. C. (306.degree. F.) for period of time sufficient to sterilize the composition."

For more information, see this patent: Patel, Gaurav; Johns, Paul; Dewille, Normanella; Pereira, Suzette. Shelf-Stable, Clear Liquid Nutritional Compositions Comprising Epigallocatechin Gallate (EGCG) and Methods for Preparing the Same. U.S. Patent Number 9675097, filed October 4, 2013, and published online on June 13, 2017. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9675097.PN.&OS=PN/9675097RS=PN/9675097

Keywords for this news article include: Antiretrovirals, Milk Proteins, Lactoglobulins, ABBOTT LABORATORIES, Drugs and Therapies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
06/22 ABBOTT LABORATORIES : Patent Issued for Shelf-Stable, Clear Liquid Nutritional C..
06/22 ABBOTT LABORATORIES : Researchers at Abbott Laboratories Target Heart Disease (T..
06/22 ABBOTT LABORATORIES : New Cytokines Findings from Abbott Laboratories Reported (..
06/21 ABBOTT : Hosts Conference Call for Second-Quarter Earnings
06/20 ABBOTT LABORATORIES : Submission of Matters to a Vote of Security Holders (form ..
06/16 ABBOTT LABORATORIES : Broadens Product Offering in Coagulation with Expanded Lau..
06/16 ABBOTT LABORATORIES : Introduces the Alinity hq Hematology Analyzer, the Newest ..
06/15 ABBOTT LABORATORIES : An Application for the Trademark "PRO SCIENCE FINISH" Has ..
06/15 ABBOTT LABORATORIES : Trademark Application for "SIMILAC SENSITIVE" Filed by Abb..
06/15 ABBOTT LABORATORIES : Trademark Application for "ENSURE" Filed by Abbott Laborat..
More news
Sector news : Pharmaceuticals - NEC
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/21 Buying Dividend Growth Stocks Without Looking - More Than 2 Years Later
06/16 RISK ARBITRAGE TODAY : What If Rite Aid Deal Doesn't Happen?
06/15 VIG Never Looked So Dividend-y
06/15 STRYKER : Growth At A More Than Reasonable Price
06/14 Top Holdings Of Dividend ETFs (June 2017 Edition)
Advertisement
Financials ($)
Sales 2017 26 375 M
EBIT 2017 5 725 M
Net income 2017 2 939 M
Debt 2017 15 411 M
Yield 2017 2,23%
P/E ratio 2017 31,69
P/E ratio 2018 24,86
EV / Sales 2017 3,78x
EV / Sales 2018 3,52x
Capitalization 84 282 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 49,0 $
Spread / Average Target 0,81%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES26.45%84 629
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
More Results